Navigation Links
Cardica Announces Fiscal 2012 First Quarter Financial Results
Date:10/27/2011

REDWOOD CITY, Calif., Oct. 27, 2011 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today announced financial results for its fiscal first quarter ended September 30, 2011. Cardica's management will host a conference call at 4:30 p.m. Eastern Time today to discuss the financial results and provide an update on the company's business.

"With the recent addition to our leadership team of Dr. Swanstrom, a world-renowned key opinion leader in laparoscopic surgery, and Chris Littel, a sales and marketing executive with extensive experience leading Ethicon-Endo Surgery's endoscopy marketing group, we believe we are well positioned for a selective commercial launch of our planned MicroCutter™ product line in Europe," said Bernard A. Hausen, M.D., Ph.D., president and chief executive officer of Cardica. "Our MicroCutter XPRESS™ 30 has now been used in approximately 20 procedures at two European centers, with no adverse events, and we expect usage in Europe to increase over the next several months."

"Product sales from our cardiac surgery business in the United States were negatively affected by the summer months, when we often experience a slow-down, as well as staffing changes in our sales organization," continued Dr. Hausen. "We expect that once we return to our full number of direct sales representatives, cardiac surgery product sales will begin to increase again to approximately $1 million per quarter."

Recent Highlights and Accomplishments

  • European physicians performed approximately 20 laparoscopic surgical procedures with the MicroCutter XPRESS 30;
  • Appointed Lee Swanstrom, M.D., F.A.C.S., as medical director of Cardica, to assist in developing its clinical and launch strategy for its MicroCutter product line and train surgeons around the world on the use and benefits of the MicroCutter XPRESS 30;
  • Appointed Christopher Littel as vice president, sales and marketing, responsible for all aspects of sales and marketing strategy for all Cardica products;
  • Signed a distribution agreement with Century Medical for Cardica's planned MicroCutter product line in Japan;
  • Received an up to $4 million loan commitment from Century Medical in exchange for distribution rights;
  • Achieved the first MicroCutter milestone under our distribution agreement and loan commitment with Century Medical, allowing us to draw the first $2 million under the  loan commitment;
  • Increased cumulative worldwide shipments of PAS-Port® Proximal Anastomosis Systems to over 25,000 units, with 980 units shipped in the fiscal 2012 first quarter; and
  • Increased cumulative worldwide shipments of C-Port® Distal Anastomosis Systems to over 12,400 units, with 275 units shipped in the fiscal 2012 first quarter.

  • Fiscal 2012 First Quarter Ended September 30, 2011 Financial ResultsTotal product sales were approximately $0.8 million for the fiscal 2012 first quarter compared to $1.0 million for the same period of fiscal 2011. License and development revenue was $84,000 in the fiscal 2012 first quarter compared to $9.0 million in the fiscal 2011 first quarter. License and development revenue for both fiscal 2011 and fiscal 2012 was related to the August 2010 license agreement with Intuitive Surgical. Total net revenue was approximately $0.9 million for the fiscal 2012 first quarter compared to $10.0 million for the fiscal 2011 first quarter. Cost of product sales was approximately $0.8 million for the fiscal 2012 first quarter compared to $0.9 million for the fiscal 2011 first quarter.

    Research and development expenses were approximately $1.6 million for the fiscal 2012 first quarter compared to $1.4 million for the fiscal 2011 first quarter. Selling, general and administrative expenses were approximately $1.5 million for both the fiscal 2012 and fiscal 2011 first quarters.  

    The net loss for the fiscal 2012 first quarter was approximately $3.0 million, or $0.11 per diluted share, compared with net income of approximately $6.2 million, or $0.24 per diluted share, for the fiscal 2011 first quarter.

    Cash and short term investments at September 30, 2011 were approximately $9.1 million compared with $9.3 million at June 30, 2011. As of September 30, 2011, there were approximately 27 million shares of common stock outstanding.  

    Conference Call DetailsTo access the live conference call today at 4:30 p.m. Eastern Time via phone, please dial 866-831-6291 from the United States and Canada or 617-213-8860 internationally. The conference ID is 96670766. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately two hours after the call through November 4, 2011, and may be accessed by dialing 888-286-8010 from the United States and Canada or 617-801-6888 internationally. The replay passcode is 93254023.

    To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's website at www.cardica.com. Please connect to the website at least 15 minutes prior to the presentation to allow for any necessary software downloads.

    The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents at www.streetevents.com, a password-protected event management site.

    About Cardica Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. Cardica's technology portfolio is intended to minimize operating time and enable minimally-invasive and robot-assisted surgeries. Cardica manufactures and markets its automated anastomosis systems, the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System, for coronary artery bypass graft (CABG) surgery and has shipped over 37,000 units throughout the world. In addition, Cardica is developing the Cardica MicroCutter XPRESS™ 30, a true multi-fire laparoscopic stapling device designed to be used in a variety of procedures, including bariatric, colorectal, thoracic and general surgery. The Cardica MicroCutter products require 510(k) review and are not yet commercially available in the U.S.

    Forward-Looking Statements This press release contains "forward-looking" statements, including all statements regarding the continued development, regulatory approval and anticipated increased usage and commercial launch of products in Cardica's proposed MicroCutter product line, including the Cardica MicroCutter XPRESS 30, as well as Cardica's expectations regarding future sales of its cardiac products. Any statements contained in this press release that are not historical facts may be deemed to be forward-looking statements. The words "believe," "expect" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Cardica's results to differ materially from those indicated by these forward-looking statements, including that Cardica may not be successful in its efforts to complete the development and commercial launch of the Cardica MicroCutter product line on Cardica's anticipated timeframe; that Cardica's current and any future products may never gain any significant degree of market acceptance; that any future Cardica products face development, regulatory, reimbursement and manufacturing risks; that Cardica's intellectual property rights may not provide adequate protection; that Cardica's sales, marketing and distribution strategy and capabilities may not be sufficient or successful; and that general business and economic conditions may impair Cardica's ability to market and develop products, as well as other risks detailed from time to time in Cardica's reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2011. Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Cardica's reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov. Cardica, Inc.Statements of Operations(amounts in thousands except per share amounts)Three months endedSeptember 30,20112010(unaudited)Revenue  Product sales, net

    $
    767$
    995  License and development revenue

    849,025  Royalty revenue

    1922Total

    87010,042Operating costs and expenses  Cost of product sales

    827944  Research and development

    1,5571,375  Selling, general and administrative

    1,5411,495Total operating costs and expenses

    3,9253,814Income (loss) from operations

    (3,055)6,228Interest and other income

    -8Interest expense

    -(13)Net income (loss)

    $
    (3,055)$
    ,223Basic net income (loss) per share

    $
    (0.11)$
    .25Diluted net income (loss) per share

    $
    (0.11)$
    .24Shares used in computing net income (loss) per share   Basic

    26,80624,623   Diluted

    26,80626,000Balance Sheets(amounts in thousands)September 30,June 30,20112011Assets

    (unaudited)Cash and cash equivalents

    $
    9,074$
    9,325Accounts receivable

    262327Inventories

    778840Other assets

    1,664978Total assets

    $
    ,778$
    ,470Liabilities and stockholders' equityAccounts payable and other liabilities

    $
    ,903$
    ,494Deferred revenue

    1,0311,114Long term debt

    2,000-Stockholders' equity

    6,8448,862Total liabilities and stockholders' equity

    $
    ,778$
    ,470
    '/>"/>

    SOURCE Cardica, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cardica Appoints Christopher Littel VP, Sales and Marketing
    2. Cardica to Announce Fiscal 2012 First Quarter Financial Results on Thursday, October 27, 2011
    3. Cardica Achieves Milestone Under Century Distribution Agreement
    4. Cardicas Cardiac Anastomosis Device Featured in Clinical Presentation on Robotic Cardiac Bypass Procedures
    5. Cardica Signs Distribution Agreement for MicroCutter in Japan
    6. Cardica Announces Fiscal 2011 Fourth Quarter and Year End Financial Results
    7. Cardica to Present at the Wedbush Life Sciences Management Access Conference
    8. Dr. Andreas Kuthe Performs First Laparoscopic Procedures Using Cardicas Microcutter XPRESS™ 30 Surgical Cutting and Stapling Device
    9. Cardica Applies CE Mark to Microcutter XPRESS™ 30 Surgical Cutting and Stapling Device
    10. Cardica Announces Fiscal 2011 Third Quarter Financial Results
    11. Cardica to Announce Fiscal 2011 Third Quarter Financial Results on Tuesday, May 10, 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/5/2016)... HARROGATE, England , February 5, 2016 ... --> Today, VoicePower Ltd - The Speech Recognition People, ... has been deployed to improve patient care, reduce turnaround times and ... ,- Wirral CCG ,- VoicePower client since 2013 Challenge: ... Challenge: --> - Six doctors ,- Wirral ...
    (Date:2/4/2016)...  Edwards Lifesciences Corporation (NYSE: EW ), the ... and critical care monitoring, announced today that it has ... Morgan Stanley & Co. LLC to repurchase $325 million ... the Company,s previously authorized program to repurchase up to ... --> --> Under the ...
    (Date:2/4/2016)... FOSTER CITY, Calif. , Feb. 4, 2016 ... (the "Company") today announced it has entered into ... and Exchange Commission (SEC) fully resolving the SEC,s ... Practices Act (FCPA).  Under the terms of the ... total of $12.8 million, including disgorgement, pre-judgment interest ...
    Breaking Medicine Technology:
    (Date:2/5/2016)... ... 05, 2016 , ... Freed-Hardeman University President Joe A. Wiley ... joint enrollment and degree completion agreement. The agreement, which begins with the ... FHU|Dickson. , The agreement allows students to be jointly admitted to both ...
    (Date:2/5/2016)... ... 05, 2016 , ... The American public tends to feel uncomfortable about drinking ... regular municipal or well water. The recent experience with lead contaminated water in Flint, ... long way toward increasing public acceptance of recycled waste water as drinking water. ...
    (Date:2/5/2016)... ... , ... At its annual meeting held last week, the American Parkinson Disease ... of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We are pleased ... APDA President and CEO. “Pat has tirelessly served APDA since 2001 when he was ...
    (Date:2/5/2016)... IL (PRWEB) , ... February 05, 2016 , ... In ... disguised form as a dream. A hallmark feature of patients with eating disorders is ... needs. The eating disorder behaviors and obsessions are regarded as maladaptive means for coping ...
    (Date:2/5/2016)... ... February 05, 2016 , ... KICVentures ( http://www.kicventures.com ... Development event in New York City on Thursday, January 21, 2016. Kingsley ... Mediacom, (both alumnus of the varsity Columbia soccer program) spoke at the event, ...
    Breaking Medicine News(10 mins):